Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target

Peter J. Cook, Rozario Thomas, Ram Kannan, Esther Sanchez de Leon, Alexander Drilon, Marc K. Rosenblum, Maurizio Scaltriti, Robert Benezra () and Andrea Ventura ()
Additional contact information
Peter J. Cook: Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center
Rozario Thomas: Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center
Ram Kannan: Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center
Esther Sanchez de Leon: Weill Cornell Graduate School of Medical Sciences of Cornell University
Alexander Drilon: Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Marc K. Rosenblum: Memorial Sloan Kettering Cancer Center
Maurizio Scaltriti: Memorial Sloan Kettering Cancer Center
Robert Benezra: Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center
Andrea Ventura: Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center

Nature Communications, 2017, vol. 8, issue 1, 1-11

Abstract: Abstract The widespread application of high-throughput sequencing methods is resulting in the identification of a rapidly growing number of novel gene fusions caused by tumour-specific chromosomal rearrangements, whose oncogenic potential remains unknown. Here we describe a strategy that builds upon recent advances in genome editing and combines ex vivo and in vivo chromosomal engineering to rapidly and effectively interrogate the oncogenic potential of genomic rearrangements identified in human brain cancers. We show that one such rearrangement, an microdeletion resulting in a fusion between Brevican (BCAN) and Neurotrophic Receptor Tyrosine Kinase 1 (NTRK1), is a potent oncogenic driver of high-grade gliomas and confers sensitivity to the experimental TRK inhibitor entrectinib. This work demonstrates that BCAN-NTRK1 is a bona fide human glioma driver and describes a general strategy to define the oncogenic potential of novel glioma-associated genomic rearrangements and to generate accurate preclinical models of this lethal human cancer.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms15987 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms15987

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms15987

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().